Actively Recruiting
Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults
Led by Qu Biologics Inc. · Updated on 2025-01-22
72
Participants Needed
1
Research Sites
146 weeks
Total Duration
On this page
Sponsors
Q
Qu Biologics Inc.
Lead Sponsor
T
The National Research Council of Canada Industrial Research Assistance Program
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is designed to test whether QBKPN SSI can improve immune function in older adults, including how well it can protect against respiratory and other infections, whether it improves the body's response to COVID-19 vaccines, what effect it has on maintaining or improving quality of life, activity level and health status and whether it has an effect on glycemic control. QBKPN is a new medication in a class known as Site-Specific Immunomodulators (SSI). SSIs are designed to train and/or improve innate immune function to reduce the risk of infections, improve immune response to cancer, and slow the progression of chronic inflammatory diseases. It is believed that QBKPN SSI can work with the immune system to help protect against respiratory and other infections.
CONDITIONS
Official Title
Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be a resident of the community or a long-term care, independent-living, or assisted living facility participating in the study
- Be aged 65 years or older
- Be able to provide written, informed consent themselves
- Male subjects engaged in vaginal intercourse with women of childbearing potential must be surgically sterile or agree to practice effective barrier contraception during the entire study treatment period and one month after last dose or agree to abstain from vaginal intercourse with women of childbearing potential during this period
You will not qualify if you...
- Life expectancy of less than 3 months due to terminal illness
- Taking biologic immunosuppressive agents or other systemic immunosuppressants except NSAIDs, colchicine, aspirin, or low-dose oral glucocorticoids
- Currently being treated or treated within 30 days for infection with systemic antibiotics or antivirals
- Known allergy or hypersensitivity to killed whole-cell bacterial vaccines
- Any condition that would preclude participation due to safety or monitoring concerns
- Treatment with experimental or investigational therapies within 3 months prior to screening or planned during study participation
- On current treatment for active malignancies or planned cancer surgery during the study period, except hormonal therapy for breast or prostate cancer or surgery for localized skin cancers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qu Biologics Trial Site
Burnaby, British Columbia, Canada, V5G 4X4
Actively Recruiting
Research Team
O
Oksana Korolova, Director, Clinical Operations
CONTACT
H
Hal Gunn, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here